Migraine is common among patients who suffer from depression, and this category of patients often needs drug treatment for both diseases. A pharmacist consulted the Regional Drug Information Centre in the western part of Norway (RELIS 3) about the combined use of sumatriptan and fluoxetine, as the product information on sumatriptan warns of a possible interaction between these drugs. This possibility was evaluated by the Drug Information Centre, and it was concluded that the combination of sumatriptan and a selective serotonin reuptake inhibitor is not contraindicated. This conclusion was based on both theoretical and clinical considerations.